Limited Offer
Nanostructured Drug Delivery Systems in Infectious Disease Treatment
- 1st Edition - July 12, 2024
- Editors: Sarwar Beg, Rahul Shukla, Mayank Handa, Mahfoozur Rahman, Ashish Dhir
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 1 3 3 3 7 - 4
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 3 3 3 6 - 7
Nanostructured Drug Delivery Systems in Infectious Disease Treatment explores a broad range of promising approaches for the treatment of infectious diseases using the latest ad… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteNanostructured Drug Delivery Systems in Infectious Disease Treatment explores a broad range of promising approaches for the treatment of infectious diseases using the latest advancements in nanomedical technologies. The book opens with an introduction about infectious diseases and global burdens. There is also specific discussion and assessment of the global impact of viruses with an emphasis on COVID-19, Zika, and Ebola. Subsequent chapters provide detailed information about various novel nanotherapeutic strategies used for delivering drugs for the treatment of various types of viral, bacterial, and fungal disorders. This will be a valuable resource for graduates, researchers, industry professionals, and anyone working to tackle the challenges of delivering drugs in a more targeted and efficient manner for the treatment of infectious diseases.
- Focuses on the application of different nanotechnology-based drug delivery systems
- Offers information on how to design and develop the nanotechnology-based drug delivery systems and devices for the treatment of infectious disorders
- Explores challenges and regulatory concerns of nanomedicine in infectious disorders
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- List of contributors
- Preface
- Chapter 1. Infectious diseases and its global epidemiology
- Abstract
- 1.1 Introduction
- 1.2 Emerging and neglected tropical infectious disease
- 1.3 Conclusions
- References
- Chapter 2. Impact assessment of virus globally: special emphasis on COVID-19, Zika, and Ebola virus
- Abstract
- 2.1 Introduction
- 2.2 Health impact
- 2.3 Global impact of Zika virus
- 2.4 Global impact of the Ebola virus
- 2.5 Learning for future challenges
- 2.6 Conclusion
- References
- Chapter 3. Nanocombinational therapies for infectious disorders
- Abstract
- 3.1 Introduction
- 3.2 Nanoparticle system
- 3.3 Multidrug delivery system for combinational therapy
- 3.4 Hurdles for codelivery of multiple antiinfectious agents in nanoplatform
- 3.5 Conclusion
- References
- Chapter 4. Stimuli responsive nanotechnological advancements in infectious disorders
- Abstract
- 4.1 Introduction
- 4.2 Infectious disorders
- 4.3 Nanotechnology in pharmaceutical research
- 4.4 Stimuli-responsive nanotechnologies in drug delivery
- 4.5 Nanotechnology for infectious disorders
- 4.6 Conclusion and future scope
- References
- Chapter 5. Application of nanotechnology based therapy against malaria
- Abstract
- 5.1 Introduction
- 5.2 Life cycle of malaria
- 5.3 Symptoms and disease complications in severe malaria
- 5.4 Nanoformulation in malaria
- 5.5 Conclusion and future perspective
- Competing interests
- Author contributions
- Data availability statement
- Consent for publication
- Acknowledgments
- References
- Chapter 6. Therapeutic potential of nano assisted delivery in tuberculosis and its management
- Abstract
- 6.1 Introduction
- 6.2 Conventional treatment options and its limitations
- 6.3 Routes of administration for nanoassisted delivery systems
- 6.4 Nanoassisted delivery systems in antituberculosis drugs
- 6.5 Biofilm penetration as novel strategy to cure tuberculosis
- 6.6 Nanoassisted drug delivery system in drug-resistant tuberculosis
- 6.7 Nanoassisted drug delivery system for host-directed therapies
- 6.8 Stimuli-responsive nanomaterials
- 6.9 Conclusion
- References
- Chapter 7. Exploration of advanced therapeutics for lymphatic and cutaneous leishmaniasis
- Abstract
- 7.1 Introduction
- 7.2 Classification of leishmaniasis
- 7.3 Current therapeutics available and challenges for leishmania
- 7.4 Advanced therapeutics for lymphatic and cutaneous leishmania
- 7.5 Nanotechnology-mediated vaccines
- 7.6 Preclinical status and status of advanced therapeutics
- 7.7 Clinical studies
- 7.8 Future prospects
- 7.9 Conclusion
- Acknowledgment
- Conflict of interest
- References
- Chapter 8. Onychomycosis with current treatment approaches: emergence of niosomes in its effective treatment
- Abstract
- 8.1 Introduction
- 8.2 Currently available therapy for onychomycosis
- 8.3 The emergence of niosomes in its effective treatment
- 8.4 Application of niosomes in onychomycosis
- 8.5 Conclusion
- References
- Chapter 9. Nanoantibiotics driven approaches as an advanced therapy for bacterial infections and chemotherapeutic resistance
- Abstract
- 9.1 Introduction
- 9.2 Development of drug resistance and failure of therapeutic regimen
- 9.3 Nanoantibiotics against bacterial and chemotherapeutic resistance
- 9.4 Nanomaterial for advanced therapies
- 9.5 Emerging nanoantibiotics for antimicrobial activity
- 9.6 Evaluative analysis between antibiotics and nanoantibiotics
- 9.7 Conclusion and future perspectives
- Competing interests
- Author contributions
- Data Availability Statement
- Consent for publication
- Acknowledgments
- References
- Chapter 10. Role of biotechnology as a theranostic tool in infectious diseases
- Abstract
- 10.1 Introduction
- 10.2 Types of theranostic tools
- 10.3 Applications and limitations of theranostic tools
- 10.4 Future directions and conclusions
- References
- Chapter 11. Nanomedicine in infectious disease challenges and regulatory concerns
- Abstract
- 11.1 Introduction
- 11.2 Infectious diseases
- 11.3 Challenges associated with the treatment of infectious diseases
- 11.4 Drug delivery and associated challenges in infectious diseases
- 11.5 Strategies to deal with the challenges
- 11.6 Nanomedicine in the treatment of infectious diseases
- 11.7 Types and properties of nanomaterial used in the preparation of nanomedicine
- 11.8 Nanoparticles in infectious diseases
- 11.9 The need for nanomedicine regulation
- 11.10 The regulatory challenges for nanomedicine
- 11.11 Global strategies for nanomedicine regulation
- 11.12 Conclusion and future prospective
- References
- Chapter 12. Role of nanotechnology derived natural products as potential therapeutics against infectious disease
- Abstract
- 12.1 Introduction
- 12.2 Outlook on infectious diseases
- 12.3 Natural products against combating infections
- 12.4 Nanotechnology and associated advantages
- 12.5 Role of nanotechnology based natural products
- 12.6 Conclusion, future perspective, and challenges
- References
- Further reading
- Chapter 13. Nanotechnology: a nanotherapeutics approach to counteracting brain infection
- Abstract
- 13.1 Introduction
- 13.2 Brain infections: types and challenges
- 13.3 Nanotechnology in medicine
- 13.4 Nanoparticles for drug delivery
- 13.5 Targeted nanotherapeutics
- 13.6 Imaging and diagnosis
- 13.7 Enhanced antibiotics and antimicrobial agents
- 13.8 Immunomodulation and brain infections
- 13.9 Biofilm disruption
- 13.10 Neuroprotection and recovery
- 13.11 Safety and ethical considerations
- 13.12 Future directions and challenges
- 13.13 Conclusion
- References
- Chapter 14. Recent advances in nanomedicines for the treatment of global infectious diseases
- Abstract
- 14.1 Introduction
- 14.2 Different types of infections
- 14.3 Classification of bacterial, viral, and fungal pathogens
- 14.4 Drug resistance
- 14.5 Nanotechnology to improve the antimicrobial delivery
- 14.6 Difficulties in treating infectious and ailments using nanotechnology
- 14.7 Targeted treatment of diseases utilizing nanoparticles
- 14.8 Conclusion
- References
- Chapter 15. Transferosomes drug delivery in topical infectious disorders
- Abstract
- 15.1 Introduction
- 15.2 Composition of transferosomes
- 15.3 Advantages and disadvantages of transferomes
- 15.4 Mechanism of action
- 15.5 Ideal characteristics of transferosomes
- 15.6 Preparation techniques for transferosomes
- 15.7 Optimization of formulation containing transferosomes
- 15.8 Characterization of transferosomes
- 15.9 Application of transferesomes in topical infectious disorder
- 15.10 Conclusion
- Conflicts of interest
- Reference
- Chapter 16. Graphene and its nanocomposites as antimicrobial potential in topical disease: state of the art
- Abstract
- 16.1 Introduction
- 16.2 Pathophysiology
- 16.3 Graphene oxide
- 16.4 Nanotechnology
- 16.5 Role of graphene and graphene oxide nanocomposites as antimicrobial potential
- 16.6 Conclusion
- References
- Chapter 17. Natural seed oil-loaded emulgel/nanogel in topical infectious disorders
- Abstract
- 17.1 Introduction
- 17.2 Topical infectious disease
- 17.3 Phytoconstituents
- 17.4 Role of natural oil-loaded nanoemulsion/nanogel in topical infectious disease
- 17.5 Conclusion
- References
- Chapter 18. Role of ferulic acid as nanomedicine in the management of various diseases
- Abstract
- 18.1 Introduction
- 18.2 Metabolism of ferulic acid
- 18.3 Ferulic acid (scavenger of nascent oxygen and free radicals)
- 18.4 Ferulic acid loaded with nanoparticles
- 18.5 Conclusion
- References
- Chapter 19. Emergence of nano-based system for effective delivery of flavonoids against topical infectious disorders
- Abstract
- 19.1 Introduction
- 19.2 Mechanism of action of flavonoid in topical infection
- 19.3 Bioavailability and toxicity of flavonoids
- 19.4 Why nanoencapsulation is necessary for cutaneous flavonoid delivery
- 19.5 Nanocarriers in their effective delivery against topical infectious disorders
- 19.6 Conclusion
- References
- Chapter 20. Key role of secondary metabolites in topical infectious disorders: nanomedicine in its effective delivery
- Abstract
- 20.1 Introduction
- 20.2 Challenges for topical drug application
- 20.3 Secondary metabolites
- 20.4 Nanocarrier as effective delivery of secondary metabolites for topical infection
- 20.5 Nanotoxicology
- 20.6 Conclusion
- References
- Chapter 21. Nanocrystals as topical applications: state of the art
- Abstract
- 21.1 Introduction
- 21.2 Drug delivery through the skin
- 21.3 Mechanism
- 21.4 Potential of a nanocrystal
- 21.5 Nanocrystal carrier system for topically active agents
- 21.6 Toxicity of nanocrystals
- 21.7 Conclusion
- References
- Index
- No. of pages: 482
- Language: English
- Edition: 1
- Published: July 12, 2024
- Imprint: Academic Press
- Paperback ISBN: 9780443133374
- eBook ISBN: 9780443133367
SB
Sarwar Beg
RS
Rahul Shukla
MH
Mayank Handa
MR
Mahfoozur Rahman
AD